137 related articles for article (PubMed ID: 25293799)
21. Impact of bacillus Calmette-Guérin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy.
Horiguchi H; Yoneyama T; Hatakeyama S; Tokui N; Sato T; Fujita N; Yamamoto H; Tobisawa Y; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Narita S; Kawaguchi T; Ohyama C
Med Oncol; 2018 Feb; 35(4):41. PubMed ID: 29480348
[TBL] [Abstract][Full Text] [Related]
22. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome.
Zieger K; Jensen KM
Scand J Urol Nephrol; 2011 Dec; 45(6):411-8. PubMed ID: 21793636
[TBL] [Abstract][Full Text] [Related]
23. [Surgical site infection by bacillus Calmette-Guerin (BCG) after radical cystectomy, occurring after intravesical bcg therapy: a case report].
Muranaka T; Kunishima Y; Shigyo M; Kato R; Masumori N; Ito N; Tsukamoto T; Takagi Y; Seki M; Toida I
Hinyokika Kiyo; 2007 Aug; 53(8):581-4. PubMed ID: 17874552
[TBL] [Abstract][Full Text] [Related]
24. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
Kim JC; Steinberg GD
J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
[TBL] [Abstract][Full Text] [Related]
25. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
26. [The recurrence of urothelial carcinoma in situ at the fossa navicularis of the urethra and the glans penis arising eight years after transurethral resection of a bladder tumor to treat superficial bladder cancer].
Nishizawa S; Inagaki T; Mori T; Kohjimoto Y; Suzuki A; Uekado Y; Shinka T
Hinyokika Kiyo; 2006 Mar; 52(3):223-6. PubMed ID: 16617879
[TBL] [Abstract][Full Text] [Related]
27. Carcinoma in situ developing in an ileal neobladder.
Ide H; Kikuchi E; Shinoda K; Mukai M; Murai M
Urology; 2007 Mar; 69(3):576.e9-11. PubMed ID: 17382181
[TBL] [Abstract][Full Text] [Related]
28. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution.
Varol C; Thalmann GN; Burkhard FC; Studer UE
J Urol; 2004 Sep; 172(3):937-42. PubMed ID: 15311003
[TBL] [Abstract][Full Text] [Related]
29. [Treatment outcome of intrarenal Bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Anan G; Suyama T; Takeuchi N; Nakamura K; Sakamoto S; Nihei N; Ichikawa T
Hinyokika Kiyo; 2013 May; 59(5):261-4. PubMed ID: 23719131
[TBL] [Abstract][Full Text] [Related]
30. [Urinary re-diversion using afferent limb as an ileal conduit for urethral recurrence after ileal neobladder reconstruction by Studer method : a case report].
Shiba M; Madono K; Tsujimoto Y; Kinouchi T
Hinyokika Kiyo; 2013 Oct; 59(10):677-81. PubMed ID: 24262711
[TBL] [Abstract][Full Text] [Related]
31. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
32. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
33. [Case of tuberculous epididymitis caused by intravesical BCG therapy].
Koizumi T; Nakanishi R; Taue R; Yamaguchi K; Nakatuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Fukumori T; Kanayama HO
Hinyokika Kiyo; 2008 Sep; 54(9):625-7. PubMed ID: 18975579
[TBL] [Abstract][Full Text] [Related]
34. [Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Okubo K; Ishitoya S; Maeda H; Suzuki Y; Arai Y
Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):386-90. PubMed ID: 9125861
[TBL] [Abstract][Full Text] [Related]
35. Review of Mayo Clinic experience with carcinoma in situ.
Zincke H; Utz DC; Farrow GM
Urology; 1985 Oct; 26(4 Suppl):39-46. PubMed ID: 3931327
[TBL] [Abstract][Full Text] [Related]
36. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder tumor: experience of 13 cases].
Okuno H; Shirahase T; Kihara Y; Arai Y
Hinyokika Kiyo; 1989 Sep; 35(9):1503-7. PubMed ID: 2816616
[TBL] [Abstract][Full Text] [Related]
37. [Intracavitary bacillus Calmette-Guerin therapy for upper tract transitional cell carcinoma].
Mori H; Miyaji B; Takahashi M; Matsuda K; Tsuka H; Wada O; Aoki Y; Akino H; Muranaka K; Kanamaru H; Okada K; Imamura Y
Hinyokika Kiyo; 1996 Apr; 42(4):257-61. PubMed ID: 8693956
[TBL] [Abstract][Full Text] [Related]
38. Cystectomy with orthotopic ileal neobladder reconstruction for treatment of bladder contracture after intravesical bacillus Calmette-Guerin therapy.
Vetorazzo Filho JE; Bahia LA; Vedovato BC; Maron PE; Esteves PE; Fernandes Rde C; Perez MD
Einstein (Sao Paulo); 2014; 12(4):502-4. PubMed ID: 25628205
[TBL] [Abstract][Full Text] [Related]
39. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
[TBL] [Abstract][Full Text] [Related]
40. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
